S&P 500 Futures
(0.15%) 5 139.25 points
Dow Jones Futures
(0.10%) 38 481 points
Nasdaq Futures
(0.23%) 17 887 points
Oil
(-0.19%) $83.69
Gas
(0.99%) $1.942
Gold
(0.30%) $2 354.20
Silver
(0.61%) $27.70
Platinum
(1.70%) $937.80
USD/EUR
(-0.18%) $0.933
USD/NOK
(-0.30%) $10.99
USD/GBP
(-0.29%) $0.798
USD/RUB
(1.25%) $93.02

Actualizaciones en tiempo real para Botanix Pharmaceuticals [BOT.AX]

Bolsa: ASX Industria: Pharmaceuticals, Biotechnology & Life Sciences
Última actualización29 abr 2024 @ 02:10

4.76% $ 0.220

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 02:10):

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections...

Stats
Volumen de hoy 3.27M
Volumen promedio 2.56M
Capitalización de mercado 346.53M
EPS $0 ( 2024-02-25 )
Próxima fecha de ganancias ( $0 ) 2024-07-28
Last Dividend $95.85 ( 1996-10-03 )
Next Dividend $0 ( N/A )
P/E -22.00
ATR14 $0.00200 (0.93%)

Volumen Correlación

Largo: 0.12 (neutral)
Corto: 0.22 (neutral)
Signal:(40.465) Neutral

Botanix Pharmaceuticals Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Botanix Pharmaceuticals Correlación - Moneda/Commodity

The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.44
( neutral )

Botanix Pharmaceuticals Finanzas

Annual 2023
Ingresos: $914 973
Beneficio Bruto: $-3.05M (-332.90 %)
EPS: $-0.00790
FY 2023
Ingresos: $914 973
Beneficio Bruto: $-3.05M (-332.90 %)
EPS: $-0.00790
FY 2022
Ingresos: $2.75M
Beneficio Bruto: $2.61M (94.79 %)
EPS: $-0.0135
FY 2021
Ingresos: $0.00
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-0.00438

Financial Reports:

No articles found.

Botanix Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Botanix Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $81.28 1994-02-18
Last Dividend $95.85 1996-10-03
Next Dividend $0 N/A
Payout Date 1996-10-25
Next Payout Date N/A
# dividends 6 --
Total Paid Out $510.23 --
Avg. Dividend % Per Year 0.00% --
Score 1.06 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-11-04)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
1.06
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WTC.AX Ex Dividend Knight 2023-09-08 Semi-Annually 0 0.00%
FEX.AX Ex Dividend Knight 2023-09-01 Annually 0 0.00%
PMC.AX Ex Dividend Junior 2023-08-24 Semi-Annually 0 0.00%
ARB.AX Ex Dividend Knight 2023-10-05 Semi-Annually 0 0.00%
IDX.AX Ex Dividend Junior 2023-08-31 Semi-Annually 0 0.00%
SCG.AX Ex Dividend Junior 2023-08-17 Annually 0 0.00%
CAR.AX Ex Dividend Knight 2023-09-15 Semi-Annually 0 0.00%
MAD.AX Ex Dividend Knight 2023-09-19 Semi-Annually 0 0.00%
TER.AX Ex Dividend Junior 2023-06-08 Annually 0 0.00%
CTE.AX Ex Dividend Knight 2023-09-07 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-11.081.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.2101.200-7.01-8.41[0 - 0.3]
returnOnEquityTTM-0.2931.500-4.37-6.56[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM9.500.80010.008.00[1 - 3]
quickRatioTTM8.090.80010.008.00[0.8 - 2.5]
cashRatioTTM7.991.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM-858.831.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-0.007022.00-0.00234-0.00468[0 - 30]
freeCashFlowPerShareTTM-0.01862.00-0.00932-0.0186[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM-5.761.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-11.101.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.01900.800-3.21-2.57[0.5 - 2]
Total Score-3.67

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-31.581.000-3.290[1 - 100]
returnOnEquityTTM-0.2932.50-2.81-6.56[0.1 - 1.5]
freeCashFlowPerShareTTM-0.01862.00-0.00621-0.0186[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.007022.00-0.00234-0.00468[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.1061.500-2.620[0.5 - 2]
operatingCashFlowSalesRatioTTM-11.171.000-10.000[0.1 - 0.5]
Total Score-2.43

Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico